The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

近年来，全球肿瘤研究与诊疗领域仿若被按下了“加速键”，呈现出一派蓬勃发展之势，为无数患者带来新的希望曙光。

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...

Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...

SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more ...

Encouragingly, intratumoral delivery of recombinant calreticulin or systemic delivery of phosphatase 1 inhibitors in combination with conventional cytotoxic agents such as etoposide or mitomycin C ...

Youdao, Inc. ("Youdao" or the "Company") , an intelligent learning company with industry-leading technology in China, today announced that it will report its fourth quarter and fiscal year 2024 ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for its lung cancer treatments, Imfinzi and Tagrisso, benefiting patients across ...

Meanwhile, Imfinzi has been recommended in combination with the chemotherapy etoposide and either carboplatin or cisplatin for the treatment of adults with untreated extensive-stage small cell lung ...

2015). VTD enhances the transactivation of cytoplasmic UBXN2A, where UBXN2A binds and inhibits mot-2 oncoprotein. The combination of VTD with a suboptimal dose of the standard chemotherapy, ...